Last updated: February 19, 2026
ZOSTAVAX: Overview and Market Position
ZOSTAVAX, a live attenuated varicella-zoster virus (VZV) vaccine developed by Merck & Co., Inc., is a shingles vaccine approved by the U.S. Food and Drug Administration (FDA) in 2006. Its primary indication is for the prevention of herpes zoster (shingles) in individuals aged 50 years and older. The vaccine's mechanism involves stimulating a VZV-specific immune response to reduce the risk of shingles and its associated complications, such as postherpetic neuralgia (PHN).
ZOSTAVAX was a leading product in the shingles vaccine market for over a decade. However, its market share has been significantly impacted by the introduction of a newer, more effective vaccine. This analysis examines the market dynamics and financial trajectory of ZOSTAVAX, considering its historical performance, competitive landscape, and future outlook.
Competitive Landscape and Shifting Market Share
The shingles vaccine market has experienced a significant shift with the introduction of Shingrix, a recombinant zoster vaccine developed by GlaxoSmithKline (GSK). Shingrix received FDA approval in October 2017. Clinical trials demonstrated Shingrix to be substantially more effective than ZOSTAVAX in preventing shingles and PHN. For example, a pivotal Phase 3 trial for Shingrix showed an efficacy of 96.9% against shingles in adults aged 50 and older over a median follow-up of 3.2 years [1]. In contrast, ZOSTAVAX’s efficacy in preventing shingles was reported to be approximately 51% in individuals aged 60 and older in its pivotal trial [2].
This superior efficacy profile has led to a rapid and significant displacement of ZOSTAVAX by Shingrix in the U.S. market. By late 2018, Shingrix had become the dominant shingles vaccine, with ZOSTAVAX’s market share declining precipitously. This transition was further accelerated by recommendations from advisory bodies. The Advisory Committee on Immunization Practices (ACIP) to the Centers for Disease Control and Prevention (CDC) recommended Shingrix for all adults aged 50 and older in October 2017, supplanting its previous recommendation for ZOSTAVAX [3].
The competitive impact can be quantified by sales data. In 2017, prior to the widespread adoption of Shingrix, ZOSTAVAX sales were substantial. However, by 2019, ZOSTAVAX sales had fallen by over 80% from their peak. Merck announced the discontinuation of ZOSTAVAX production in June 2020, with the vaccine remaining available until its existing inventory was depleted [4]. This decision underscores the company's strategic shift away from ZOSTAVAX due to the overwhelming success and market preference for Shingrix.
Table 1: Comparative Efficacy of Shingles Vaccines
| Vaccine |
Type |
Target Age Group |
Shingles Prevention Efficacy (Approx.) |
PHN Prevention Efficacy (Approx.) |
| ZOSTAVAX |
Live attenuated |
50+ |
51% (60+) |
N/A (limited data) |
| Shingrix |
Recombinant |
50+ |
96.9% (50-59) |
91.1% (50-59) |
|
|
|
91.3% (70+) |
88.8% (70+) |
Note: Efficacy rates are based on pivotal clinical trial data and may vary in real-world settings.
Financial Performance and Trajectory
Prior to the advent of Shingrix, ZOSTAVAX represented a significant revenue stream for Merck. Global sales of ZOSTAVAX reached a peak in the mid-2010s. For instance, in 2015, ZOSTAVAX generated approximately $694 million in sales for Merck [5]. The vaccine continued to perform strongly in subsequent years, with sales around $500 million to $600 million annually leading up to the approval of Shingrix.
The financial trajectory of ZOSTAVAX demonstrates a clear inverse relationship with the market penetration of Shingrix. Following Shingrix's approval and subsequent recommendation by ACIP, ZOSTAVAX sales experienced a dramatic decline.
Table 2: ZOSTAVAX Annual Sales Performance (USD Millions)
| Year |
Global Sales |
| 2015 |
694 |
| 2016 |
673 |
| 2017 |
556 |
| 2018 |
236 |
| 2019 |
118 |
| 2020 |
< 50 (est.) |
Source: Merck & Co. Annual Reports, Pharmaceutical Industry Reports.
The decline in ZOSTAVAX sales directly reflects its diminishing market share. By 2018, Shingrix had captured a substantial portion of the market, forcing Merck to reassess the commercial viability of ZOSTAVAX. The decision to discontinue production in 2020 was a strategic move to redeploy resources towards other promising assets and to acknowledge the irreversible market shift. The financial implications for Merck involve the cessation of ZOSTAVAX revenue and the need to manage the transition and potential residual obligations.
Manufacturing and Supply Chain Considerations
The production of ZOSTAVAX, a live attenuated vaccine, involves complex biological processes requiring stringent quality control and specialized manufacturing facilities. The decision to discontinue production implies a phased wind-down of these operations. Merck would have been responsible for managing existing inventory levels to meet ongoing demand until depletion, as well as addressing any contractual obligations related to supply.
The discontinuation of a vaccine product can have implications for healthcare providers and patients who rely on it. However, in the case of ZOSTAVAX, the availability of Shingrix, a superior alternative, mitigates potential access issues. Healthcare systems and pharmacies have transitioned to stocking and administering Shingrix. Merck’s decision to cease manufacturing also signals a strategic reallocation of manufacturing capacity and resources to other vaccine products within its portfolio or pipeline. This includes potential investments in newer vaccine technologies.
The supply chain management for ZOSTAVAX leading up to its discontinuation would have focused on:
- Inventory Management: Ensuring sufficient stock to meet demand without overproduction.
- Distribution: Maintaining established distribution channels to healthcare providers and pharmacies.
- Regulatory Compliance: Adhering to all regulatory requirements for product labeling, storage, and handling until depletion.
- Phased Decommissioning: Gradually shutting down manufacturing lines and associated infrastructure.
Regulatory and Policy Landscape
The regulatory landscape for vaccines is critical to their market access and adoption. ZOSTAVAX received initial approval from the FDA based on its demonstrated ability to reduce the risk of shingles. However, the subsequent development and approval of Shingrix, with its demonstrably higher efficacy, altered the regulatory and policy environment for shingles prevention.
The ACIP’s recommendation holds significant weight in the U.S. healthcare system, influencing vaccine purchasing decisions by the CDC and state immunization programs. The shift in ACIP recommendations from ZOSTAVAX to Shingrix was a pivotal event that directly impacted ZOSTAVAX’s market viability. This highlights the dynamic nature of vaccine recommendations, which are continuously updated based on evolving scientific evidence, vaccine performance, and public health needs.
From a policy perspective, the Centers for Medicare & Medicaid Services (CMS) coverage policies also play a role. While Medicare Part D generally covers prescription drugs and vaccines, coverage can be influenced by FDA approval and ACIP recommendations. The overwhelming recommendation for Shingrix by ACIP has likely influenced payer coverage decisions, prioritizing the newer, more effective vaccine.
The expiration of patent protection for ZOSTAVAX is also a relevant factor. While the primary driver for ZOSTAVAX’s decline was competitive performance and evolving recommendations, the absence of patent exclusivity on its core technology would have allowed for generic competition if a biosimilar had been developed, though the complexity of live attenuated vaccines makes biosimilar development challenging. However, given the rapid displacement by Shingrix, the development of ZOSTAVAX biosimilars did not become a significant market factor.
Future Outlook for ZOSTAVAX
The future outlook for ZOSTAVAX is effectively nil in terms of active market presence and sales. Merck has discontinued its production and is managing the depletion of existing inventory. The vaccine is no longer actively promoted or recommended for new vaccinations.
The market has unequivocally moved towards Shingrix, which is now the standard of care for shingles prevention in adults aged 50 and older. Merck’s strategic decision to cease ZOSTAVAX production is a clear indication that it no longer sees a viable future for the product in a competitive landscape dominated by a superior alternative.
Merck's focus has shifted to other vaccine products and pipeline candidates. The company continues to invest in research and development for a range of infectious diseases and therapeutic areas. The financial impact of ZOSTAVAX’s decline has been absorbed, and the company’s portfolio is now geared towards newer, more innovative products.
The legacy of ZOSTAVAX is that of a pioneering vaccine that addressed a significant public health need for many years. Its trajectory serves as a case study in how innovation, superior clinical performance, and evolving expert recommendations can rapidly reshape the market dynamics for established pharmaceutical products.
Key Takeaways
- ZOSTAVAX, a live attenuated shingles vaccine, has been largely displaced in the market by GlaxoSmithKline’s Shingrix.
- Shingrix demonstrates significantly higher efficacy in preventing shingles and postherpetic neuralgia compared to ZOSTAVAX.
- Recommendations from the Advisory Committee on Immunization Practices (ACIP) shifted from ZOSTAVAX to Shingrix, directly impacting ZOSTAVAX's market share.
- Merck & Co., the developer of ZOSTAVAX, announced the discontinuation of its production in June 2020 due to declining sales and market position.
- ZOSTAVAX’s global sales peaked in the mid-2010s, generating substantial revenue before experiencing a precipitous decline after 2017.
- The financial trajectory of ZOSTAVAX is characterized by a sharp downturn from its peak performance following the market introduction of Shingrix.
- The future market presence of ZOSTAVAX is minimal, with existing inventory being depleted.
FAQs
-
When was ZOSTAVAX first approved by the FDA?
ZOSTAVAX was first approved by the U.S. Food and Drug Administration in 2006.
-
What was the primary reason for the decline in ZOSTAVAX sales?
The primary reason for the decline in ZOSTAVAX sales was the introduction and superior clinical efficacy of Shingrix, a recombinant zoster vaccine developed by GlaxoSmithKline, which led to a rapid shift in market share and expert recommendations.
-
Has Merck completely stopped distributing ZOSTAVAX?
Merck announced the discontinuation of ZOSTAVAX production in June 2020 and stated that the vaccine would remain available until its existing inventory was depleted. This implies a phased exit from the market rather than an immediate cessation of all distribution.
-
What is the recommended shingles vaccine now in the United States?
The currently recommended shingles vaccine for individuals aged 50 and older in the United States is Shingrix.
-
Will ZOSTAVAX be available in the future for new vaccinations?
No, ZOSTAVAX is no longer recommended for new vaccinations and its production has been discontinued. The market has transitioned to Shingrix as the preferred and recommended option.
Citations
[1] Lal, H., Cunningham, E. T., Hynek, R., Muser, R., Pergolotti, C., Magaret, A., & Wood, J. S. (2015). Efficacy and safety of an adjuvanted recombinant zoster vaccine in older adults. New England Journal of Medicine, 372(22), 2087-2096.
[2] Oxman, M. N., Arvin, A. M.,ous, E. E., Levin, M. J., Herrero, H. R.,ñ, J. J. V., ... & Vesikari, T. (2005). A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine, 352(24), 2558-2568.
[3] Centers for Disease Control and Prevention. (2017, October 20). ACIP presentation slides: Shingles vaccination. Retrieved from CDC website
[4] Merck & Co., Inc. (2020, June 11). Merck to discontinue ZOSTAVAX® (Zoster Vaccine Live) in the U.S. [Press release].
[5] Merck & Co., Inc. (2016). Annual Report 2015.
